6 - 7 March 2015, Tunis, Tunisia

Course Objectives

• To increase knowledge about viral hepatitis
• To review the epidemiology, prevention and outcome of viral hepatitis
• To enhance attendees' understanding of diagnosis of hepatitis
• To increase knowledge about the treatment of viral hepatitis and follow-up
• To demonstrate through case discussions all the steps of diagnosis and treatment of chronic viral hepatitis

Course Venue

Concorde les Berges du Lac Hotel
Rue du Lac Turkana
1053 Tunis
Tunisia

Phone +216 71 961 951
Fax +216 71 960 607
bergesdulac[at]concorde-hotels.com
www.hotelconcorde-bergesdulac.com

Target Audience

25 – 50 infectious disease and clinical microbiology specialists and trainees, gastroenterologists and clinicians taking care of patients with viral hepatitis.

CME Accreditation

The organisers of the course will apply for European CME accreditation through EACCME.

Contact Person (Scientific Programme)

Prof Badreddine Kilani
Department of Infectious Diseases
Rabta Hospital
University El Manar
Tunis
Tunisia

Phone +216 715 788 22
Fax +216 715 749 18
badreddine.kilani[at]rns.tn

Administrative Secretariat

Bahri Touil
Mice Travel
8, Rue Omar El Mokhtar
1082 Mutuelleville
Tunis
Tunisia

Phone +216 712 828 27
Fax +216 712 837 38
mice[at]planet.tn

Presentations are availabe in the ESCMID Online Lecture Library.

Friday, 6 March 2015
09:00 Opening session
How to deal with guidelines for hepatitis C treatment
09:15 EASL and AASLD recommendations: what’s new? D. Salmon
09:45 Management of patients in resource limited settings. H. Leblebicioglu
10:15 Current treatment options for HCV genotype 2 – 6. M. Puoti
10:45 Coffee break
Challenges from a new era in hepatitis C treatment
11:00 HCV diagnosis and monitoring in the era of direct-acting antiviral agents.
           W. Irving
11:30 Viral and host factors predictive of sustained viral response. J. E. Arends
12:00 Epidemiology and risk factors of acute HCV. D. Salmon
12:30 Acute HCV infection: when to treat & how to treat? B. Rijnders
13:00 Lunch
14:30 Update on future strategies for HCV cure and eradication. T. Asselah
Round table: case studies
15:00 Interferon free regimen in cirrhotic patients. V. Ghisetti & A. Ustianowski
16:00 Coffee break
16:15 HCV management in people who inject drugs. J. E. Arends
17:15 Difficult to treat patients (elderly, transplant recipients). P. Sogni

Saturday, 7 March 2015
Special issues in hepatitis B
09:00 Hepatitis B virus: life cycle with old and new targets for antiviral therapy.
           A. Ustianowski
09:30 HBV/HDV: interferon or combination with nucleoside analogs and new                     treatment strategies. P. Sogni
10:00 Prophylaxis of hepatitis B and pregnancy. L. Ammari
10:15 Update on hepatitis B vaccination. R. Abdelmalek
10:30 Coffee break
Challenges from other hepatitis virus infections
10:45 Treatment of HBV in HIV-infected patients: opportunities and challenges.
           J. E. Arends
11:15 Diagnosis and prevention of hepatitis E. H. Dalton
11:45 HEV in immunocompromised patients. B. Kilani
12:15 What’s new in delta hepatitis? J. Boubacar
12:45 Lunch
Round table: case studies
14:00 Non-invasive fibrosis tests: from discovery to clinical applicability. N. Guha
14:45 Difficult to treat patients in chronic hepatitis B: do they still exist?
           R. Ozaras
15:30 Coffee break
15:45 Immunosuppression and hepatitis B virus reactivation. H. Leblebicioglu
16:30 Closing session

Invited Faculty Members

• R. Abdelmalek, Tunis, Tunisia
• L. Ammari, Tunis, Tunisia
• J. E. Arends, Utrecht, Netherlands
• T. Asselah, Paris, France
• J. Boubacar, Tunis, Tunisia
• H. Dalton, Truro, United Kingdom
• V. Ghisetti, Turin, Italy
• N. Guha, Nottingham, United Kingdom
• W. Irving, Nottingham, United Kingdom
• B. Kilani, Tunis, Tunisia
• H. Leblebicioglu, Samsun, Turkey
• R. Ozaras, Istanbul, Turkey
• M. Puoti, Milan, Italy
• B. Rijnders, Rotterdam, Netherlands
• D. Salmon, Paris, France
• P. Sogni, Paris, France
• A. Ustianowski, Manchester, United Kingdom